Fibrinogen αC-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis by McPherson, H.R. et al.
This is a repository copy of Fibrinogen αC-subregions critically contribute blood clot fibre 
growth, mechanical stability, and resistance to fibrinolysis.




McPherson, H.R., Duval, C., Baker, S.R. et al. (10 more authors) (2021) Fibrinogen αC-
subregions critically contribute blood clot fibre growth, mechanical stability, and resistance 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
McPherson et al. eLife 2021;10:e68761. DOI: https:// doi. org/ 10. 7554/ eLife. 68761  1 of 20
Fibrinogen αC- subregions critically 
contribute blood clot fibre growth, 
mechanical stability, and resistance 
to fibrinolysis
Helen R McPherson1, Cedric Duval1, Stephen R Baker2, Matthew S Hindle1, 
Lih T Cheah1, Nathan L Asquith3, Marco M Domingues4, Victoria C Ridger5, 
Simon DA Connell6, Khalid M Naseem1, Helen Philippou1, Ramzi A Ajjan1, 
Robert AS Ariëns1*
1Discovery and Translational Science Department, Leeds Institute of Cardiovascular 
and Metabolic Medicine, University of Leeds, Leeds, United Kingdom; 2Department 
of Physics, Wake Forest University, Winston Salem, United States; 3Division of 
Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, 
United States; 4Instituto de Medicina Molecular - João Lobo Antunes, Faculdade 
de Medicina, Universidade de Lisboa, Lisbon, Portugal; 5Department of Infection, 
Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United 
Kingdom; 6Molecular and Nanoscale Physics Group, University of Leeds, Leeds, 
United Kingdom
Abstract Fibrinogen is essential for blood coagulation. The C- terminus of the fibrinogen α-chain 
(αC- region) is composed of an αC- domain and αC- connector. Two recombinant fibrinogen variants 
(α390 and α220) were produced to investigate the role of subregions in modulating clot stability and 
resistance to lysis. The α390 variant, truncated before the αC- domain, produced clots with a denser 
structure and thinner fibres. In contrast, the α220 variant, truncated at the start of the αC- connector, 
produced clots that were porous with short, stunted fibres and visible fibre ends. These clots were 
mechanically weak and susceptible to lysis. Our data demonstrate differential effects for the αC- sub-
regions in fibrin polymerisation, clot mechanical strength, and fibrinolytic susceptibility. Furthermore, 
we demonstrate that the αC- subregions are key for promoting longitudinal fibre growth. Together, 
these findings highlight critical functions of the αC- subregions in relation to clot structure and 
stability, with future implications for development of novel therapeutics for thrombosis.
Introduction
Fibrinogen is a major component of the blood, normally circulating at concentrations between 1.5 
and 4 mg/mL (Bridge et al., 2017). The fibrinogen molecule is composed of two pairs of three chains 
each (Aα2Bβ2γ2). The N- termini of these chains form the central E- region, with the Aα- and Bβ-chain 
N- termini forming the fibrinopeptides A and B (FpA and FpB), respectively. The E- region is connected 
to two distal D- regions by two coiled- coil regions comprising all three chains. While the C- termini 
of the Bβ- and γ-chains end in the D- region, the Aα-chains extend for a substantial length from the 
D- region (Undas and Ariëns, 2011). This extension is known as the αC- region and is composed of 
two main subsections, a highly flexible αC- connector (α221-α391) and a globular domain known as 
the αC- domain (α392-α610) (Tsurupa et al., 2002).
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The majority of the fibrinogen molecule has been resolved by crystallography with the exception 
of the N- termini of all three chains, and the C- terminus of the Bβ- (residues 459–461) and γ-chain 
(residues 395–411) (Weisel and Litvinov, 2017). The αC- region is the largest unresolved section, 
which is likely due to its intrinsically disordered nature (Spraggon et al., 1997; Kollman et al., 2009). 
This region has previously been characterised in some detail by nuclear magnetic resonance, atomic 
force microscopy (AFM), and transmission electron microscopy (Veklich et al., 1993; Burton et al., 
2006; Protopopova et al., 2015; Protopopova et al., 2017). The αC- connector is the least struc-
tured of this region and connects the coiled- coil region to an αC- domain (Weisel and Medved, 2001; 
Tsurupa et al., 2002). The αC- domain forms a compact structure with two subdomains Aα392–503 
and Aα504–610, with Aα392–503 containing a series of β-sheets (Tsurupa et al., 2009). In its native 
structure, the αC- domain of fibrinogen has been shown to associate with the central E- region through 
electrostatic interactions and is released by thrombin through FpB cleavage (Veklich et al., 1993; 
Litvinov et al., 2007).
Fibrinogen is converted to fibrin by thrombin to form a fibrin fibre network, which incorporates red 
blood cells (RBCs) and platelets to produce a clot that prevents blood loss following vascular injury. 
Thrombin first cleaves FpA, allowing for the formation of fibrin oligomers, and protofibrils (Weisel 
and Litvinov, 2017). FpB is cleaved by thrombin at a slightly slower rate, facilitating the release of the 
αC- region and resulting in interactions between adjacent αC- regions to promote lateral protofibril 
aggregation and fibre diameter growth (Cilia La Corte et al., 2011; Weisel and Litvinov, 2017). The 
clot is further stabilised by activated factor XIII (FXIII)- mediated cross- linking of the α- and γ-chains 
(Pisano et al., 1968).
Previous investigations into the function(s) of the αC- region have been based on recombinant 
fibrinogen (α251), proteolytic digestion products of fibrinogen (fragment X), and dysfibrinogenemia 
variants, including Marburg, Lincoln, Mahdia, Milano III, and Otago (Koopman et al., 1992; Gorkun 
et al., 2002; Furlan et al., 1994; Ridgway et al., 1996; Ridgway et al., 1997; Gorkun et al., 1998; 
Collet et al., 2005; Amri et al., 2017). In the case of dysfibrinogenemia, data can be challenging to 
interpret due to a number of factors such as patients not always being homozygous, the presence of 
a combination of fibrinogen species in the plasma, insertion of additional residues into the α-chain, 
and/or low circulating levels of fibrinogen, in addition to heterogeneity in post- translational fibrinogen 
modifications between individuals (Koopman et al., 1992; Ridgway et al., 1996; Ridgway et al., 
1997; Amri et al., 2017). Investigations with proteolytic fragments, dysfibrinogenemia samples, and 
recombinant fibrinogen have provided some insights into the possible roles of the fibrinogen αC- re-
gion. These include effects on fibrinolysis rates, lateral aggregation, and fibre thickness, in addition 
to effects on FXIII cross- linking and the mechanical stability of the clots (Gorkun et al., 2002; Gorkun 
et al., 1998; Collet et al., 2005; Tsurupa et al., 2009; Helms et al., 2012). However, the respective 
roles of each of the two sections of the αC- region (the connector and the αC- domain) are hitherto 
unexplored.
We hypothesise that the connector and the αC- domain have differential effects on fibrin clot 
network properties, and our work explores the functional role of these two key subregions of the 
αC- region by producing two recombinant α220 and α390 fibrinogen variants in a mammalian expres-
sion system. Fibrinogen α390 was truncated before the start of the αC- domain and therefore lacks the 
C- terminal domain, while α220 was truncated at the start of the α-connector, resulting in the removal 
of the entire αC- region. Through the use of these truncated fibrinogens, we aimed to gain a greater 
understanding of how each αC- subregion influences blood clot structure and function.
Results
Impact of αC-subregions on clot structure
The structural differences between WT fibrinogen and the two truncated variants are shown by sche-
matic images (Figure 1A). The α390 variant is truncated just before the start of αC- domain, whereas 
the α220 variant is truncated at the start of the αC- connector and therefore lacks both subregions. The 
nature of the fibrinogen variants with deletions to the αC- subregions was confirmed by native PAGE 
and reducing SDS- PAGE (Figure 1B and C). Both fibrinogen truncations migrated further compared to 
WT, with α220 electrophoresing the furthest (Figure 1B), in agreement with their reduced molecular 
weight. One band was observed for each sample, indicating homogeneous species. The WT showed 
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no difference in migration compared with plasma- purified fibrinogen (Figure 1—figure supplement 
1). Reducing SDS- PAGE confirmed that the lower molecular weight was due to truncation of the 
fibrinogen α-chain (Figure 1C), whilst both β- and γ-chains migrated to the same point as the respec-
tive chains of WT fibrinogen. The reduced molecular weight of the α-chains was 42 kDa for α390 and 
25 kDa for α220, as predicted, with the calculated molecular weights for the hexameric (Aα2Bβ2γ2)- 
truncated fibrinogens being 290 kDa and 256 kDa, respectively.
Figure 1. Initial characterisation of the recombinant truncated fibrinogen. (A) Schematic of WT, α390, and α220 highlighting the differences in structure 
of αC- region. (B) Native PAGE gel of the recombinant fibrinogens showed increased migration with decreasing protein size, and a single band for each 
fibrinogen α-chain variant and WT. (C) Reducing SDS- PAGE gel of the truncated fibrinogens, showing intact β- and γ-chains, and the correct size 
for the α-chains. All preparations showed no degradation and high purity. The arrow indicates the α-chain for α390 just underneath the γ-chain. (D) 
Turbidity curve of the truncated and WT fibrinogens showing an increase in optical density over time. (E) The maximum optical density was significantly 
reduced for α390, but not α220, compared to WT. (F) The lag phase was significantly increased for α390, then α220, compared to WT. Results shown as 
mean ± SD, n = 4, *p<0.05, ***p<0.001, ****p<0.0001 by one- way ANOVA with Dunnett’s multiple comparison test relative to WT.
The online version of this article includes the following figure supplement(s) for figure 1:
Source data 1. Raw and uncropped gels for (Figure 1A) and (Figure 1B) and turbidimetric assay data (Figure 1D,F).
Figure supplement 1. NativePAGE gel- recombinant WT (rWT) and plasma- purified WT (pWT).
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Fibrin polymerisation by turbidimetry was similar for clots produced with WT (0.385 ± 0.052 OD) 
and α220 (0.376 ± 0.029 OD, p=0.9228) fibrinogens (Figure 1D and E). In contrast, clots produced 
with α390 (0.169 ± 0.035 OD, p<0.0001) fibrinogen showed significantly reduced maximum optical 
density (Figure 1E), indicating the formation of a fibrin clot with thinner fibres and a denser struc-
ture. There was a step- wise increase in the lag phase from WT (159.5 ± 20.3 s) to α390 (193 ± 6.2, 
p=0.0143) and α220 (227.5 ± 11.4, p=0.0001) (Figure 1F).
Fibrin network structure was visualised using laser scanning confocal microscopy (LSCM), which 
showed distinct clot architectures for α390 and α220 fibrin compared with WT and each other 
(Figure 2A). In agreement with turbidimetric analysis, a denser clot structure was observed for clots 
made with α390 fibrinogen compared to WT. However, α220 clots were much more heterogeneous 
and their structure showed clumps of regions with highly branched fibres of stunted length compared 
to WT, leaving very large pores that were observed throughout. No difference in average fibre 
count was observed between WT (12.97 ± 0.35 fibre/100 µm) and α220 (14.87 ± 2.25 fibre/100 µm, 
p=0.3212) (Figure 2B), but the fibre count was significantly increased for α390 clots (19.6 ± 1.79 
fibre/100 µm, p=0.0041). Despite the clear difference in clot structure between α220 and WT, the 
Figure 2. Fibrin structural changes observed with truncation to the fibrinogen α-chain. (A) Representative laser confocal microscopy images of 
clots composed of truncated and WT fibrinogens, scale bar is 20 µm. (B) Clot fibrin fibre density was significantly increased for α390, but not α220, 
compared to WT. (C) Representative scanning electron microscopy images of clots composed of either truncated fibrinogen or WT, scale bar is 10 µm 
for ×5000 and 2 µm for the ×20,000 magnifications. Yellow arrows on the ×20,000 magnification images for α220 highlight the numerous fibre ends 
visible throughout the clot. (D) Average fibre diameter calculated from the ×20,000 magnification images showed a significantly decreased diameter 
for α390, but not α220, compared to WT. Laser scanning confocal images were taken on an LSM880 inverted laser scanning confocal microscope 
(Zeiss; Cambridge, UK) using a ×40 magnification oil objective. Scanning electron microscope images were taken on an SU8230 Ultra- High- Resolution 
Scanning Electron Microscope (Hitachi, Tokyo, Japan). Results shown as mean ± SD, n = 3 confocal and scanning electron microscopy n = 3 (α390 and 
α220) and n = 4 WT, **p<0.01 by one- way ANOVA with Dunnett’s multiple comparison test relative to WT.
The online version of this article includes the following source data for figure 2:
Source data 1. Fibre count (Figure 2B) and diameter (Figure 2D).
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average fibre count was similar, suggesting that α220 truncation affects clot organisation and fibre 
growth, but not the overall number of fibres that are initiated within the clot.
Subsequently, fibrin clot ultrastructure was investigated using SEM (Figure 2C). Consistent with 
LSCM and turbidimetric analysis, network structure for α390 was denser compared with WT clots. 
Compared to α390, clots made with α220 and WT fibrinogen had similar network densities, but 
numerous fibre ends were visible in α220 clots, which were not observed in either of the other two 
clots (Figure 2C, yellow arrows). Average fibre diameter was reduced for α390 (51.67 ± 5.03 nm, 
p=0.0059) compared to WT (79.19 ± 11.72  nm), but not for α220 (86.15 ± 2.26  nm, p=0.4801) 
(Figure 2D).
Figure 3. Early fibrin polymers length comparison. (A) Representative images of fibrin polymers lengths for truncated and WT fibrinogens at 10, 20, and 
30 min, scale bar is 1 µm. (B) Average polymer length was significantly decreased for α220, but not α390, at all time points compared to WT. Each point 
in (B) represents a single measured polymer; at least 165 polymers were measured for each time point/fibrinogen variant, and at least three replicates 
were made of each sample. Results shown as median ± IQR, ****p<0.0001 by Kruskal–Wallis test with Dunn’s multiple comparison test relative to WT.
The online version of this article includes the following source data for figure 3:
Source data 1. Oligomer lengths (Figure 3B).
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Protofibril growth
AFM was used to study the role of the αC- subregions during early polymerisation steps. Figure 3A 
shows representative early polymerisation images of the fibrinogen variants over time under diluted 
in vitro conditions to slow the reaction down from seconds to minutes. An increase in polymer length 
was observed for both WT and α390, whereas α220 showed limited polymer growth (Figure 3B). 
At 10 min, similar oligomer lengths were observed for WT (223 ± 94 nm) and α390 (240 ± 103 nm, 
p=0.3596), whereas α220 average length was shorter at 142 ± 56 nm (P < 0.0001). A similar pattern of 
reduced oligomer growth for α220 was observed at 20 min WT (319 ± 263 nm), α390 (326 ± 245 nm 
P => 0.9999) and α220 (173 ± 58 nm p < 0.0001) and 30 min WT (372 ± 284 nm), α390 (341 ± 202 nm 
P => 0.9999) and α220 (204 ± 84 nm p < 0.0001).
Clot mechanics and in vitro fibrinolysis
Next, the effect of αC- subregions on clot resistance to lysis and viscoelastic properties was inves-
tigated. Initial investigations into lysis by LSCM showed there was no defined lysis front for α220 
clots, likely due to the highly porous structure (Figure  4—figure supplement 1A) and there was 
no difference in time to 50%  lysis between WT and α390 clots (Figure 4—figure supplement 1B). 
Figure 4. αC- connector provides clot stability. (A) Normalised fibrinolysis curve over time of truncated and WT fibrinogens. (B) Time to 50%  lysis was 
significantly decreased for α220, but not α390, compared to WT. (C) Representative SDS- PAGE gels of truncated and WT fibrinogens undergoing cross- 
linking by FXIII, showing α- and γ-chain cross- linking in the variants. (D) Elastic modulus (G′) at 0.1 Hz, 1 Hz, and 10 Hz, in the absence of FXIII, showed 
that clot stiffness was not different between α390 and WT, but could not be determined (N.D) for α220. (E) Elastic modulus (G′) at 0.1 Hz, 1 Hz, and 
10 Hz, in the presence of FXIII, showed that α390 markedly increased, whilst α220 significantly decreased, clot stiffness compared to WT. n = 4. Results 
shown as mean ± SD, n = 4 for (A), (B), (D), and (E) n = 4 for WT and α390 and n = 3 in (E) for α220, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one- 
way ANOVA with Dunnett’s multiple comparison test (B) and two- way ANOVA with Dunnett’s multiple comparison test graphs (D) relative to WT.
The online version of this article includes the following source data, source code, and figure supplement(s) for figure 4:
Source code 1. Code used in MATLAB for fibrin microrheology analysis.
Source data 1. Fibrinolysis data (Figure 4A and B), raw and uncropped gels for (Figure 4C), and fibrin microrheology data for Figure 4D and E.
Figure supplement 1. Fibrinolysis by laser scanning confocal microscopy.
Figure supplement 1—source data 1. Fibrinolysis times (Figure 4—figure supplement 1B).
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To overcome the lack of a defined lysis front, lysis was studied by turbidity after layering fibrinolytic 
factors on preformed clots (Figure 4A). Time to 50%  lysis was similar for α390 and WT clots (68.6 
± 8.0 vs. 73.4 ± 4.8 min, p=0.4138), whereas α220 clot lysis was considerably faster (17.7 ± 3.3 min, 
p<0.0001) (Figure 4B).
The αC- domain contains lysines which are cross- linked by FXIII to γ-glutamyl-ε-lysyl bonds with 
glutamines in the αC- connector of adjacent fibrin molecules, some of which are still present in α390 
(Q221 [and/or 223], Q237, Q328, and Q366) (Mouapi et al., 2016; Schmitt et al., 2019). The entire 
αC- region is removed in α220, and therefore, all residues involved in cross- linking are absent. Cross- 
linking analysis by SDS- PAGE showed reductions in α-chain molecular weight over time due to the 
FpA cleavage by thrombin, noticeable in all fibrinogen variants, particularly after 15 min (Figure 4C). 
Both truncations displayed normal fibrin γ-chain cross- linking and formation of γ-γ dimers, but delayed 
α-chain cross- linking with both truncations showing un- cross- linked α-chain after 2 hr, while all α-chain 
monomer had been converted to polymer in WT. Some α-chain cross- linking may have still occurred 
even in α220 which lacks all known cross- linking residues, suggesting the presence of additional cross- 
linking sites.
Next, effects of αC- subregions on clot viscoelastic properties were investigated by magnetic 
tweezers. Without FXIII, α390 clots showed similar storage modulus (G’) at 0.1, 1, and 10  Hz 
(Figure 4D) as WT. G′ is a measure of elastic energy stored through deformation and is linked to 
clot stiffness. No viscoelastic data could be generated for α220 clots without FXIII due to highly 
porous nature of these clots and inability of superparamagnetic beads to remain trapped by 
the weak fibrin network. With FXIII, the G′ was higher for both WT and α390 than without FXIII 
(Figure  4D and E). Cross- linked α220 clots showed markedly reduced G′ over all frequencies 
compared to WT, whereas α390 clots showed higher elastic modulus compared to WT with FXIII 
at 10 Hz (Figure 4E). In experiments with and without FXIII, there was a trend for α390 having a 
higher elastic modulus compared to WT. This observation is likely due to increased fibre branching 
and clot density in this variant.
Clot contraction
To explore the role of αC- subregions in mediating interactions with blood cells, whole blood from Fga-
/- mice supplemented with variant or WT fibrinogen was analysed for clot contraction, which occurs 
secondary to platelet contractile forces pulling fibrin fibres while trapping RBCs. Clots formed and 
contracted normally for WT and α390, but no visible clot was formed for α220 (Figure 5A), and as 
a result neither clot contraction nor weight could be analysed. No difference was observed in clot 
retraction kinetics (Figure 5B) or clot weight between WT and α390 (Figure 5C).
Comparing the supernatant (activated) of contracted clots to corresponding non- activated samples 
indicated that platelets were fully incorporated into the contracted clot (Figure 5—figure supplement 
1A and B). Despite the lack of distinct clot formation, α220 showed reduced number of platelets in 
the supernatant, likely due to normal platelet activation and formation of platelet aggregates, which 
agrees with an increased FFC/SCC platelet profile in this sample. Control samples containing tissue 
factor, but no fibrinogen, also showed reduced platelet numbers in the supernatant. Control samples 
without tissue factor and fibrinogen showed similar platelet numbers for non- activated and activated 
as no clot formed and platelets were not activated. Examination of the supernatant of contracted clots 
to non- activated samples for RBC retention showed similar retention between WT and α390, while 
α220 clots demonstrated reduced RBC retention compared with WT (Figure 5D). The amount of RBC 
retention in α220 was similar to the activated control without fibrinogen, suggesting that platelet 
aggregates may be trapping some RBCs.
Next, we investigated fibrin interaction with platelets by flow cytometry. Upon ADP and PAR4 
activation, fibrinogen- positive platelets increased to the same extent for WT, α390, and α220, but 
not fibrinogen γ′, consistent with its lack of integrin- binding C- terminal AGDV motif (Figure 5—
figure supplement 2A). However, fibrinogen median fluorescence intensity (MFI) for α220 was 
decreased, suggesting reduced fibrinogen bound per platelet. In contrast, α390 displayed similar 
binding levels as WT (Figure  5—figure supplement 2B). Despite minor differences in binding, 
these data indicate that clot contraction differences are not driven by a complete inability of α220 
to bind platelets.
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Whole blood clot lysis
Thromboelastography was used to study clot formation, firmness, and fibrinolysis in whole blood 
from Fga-/- supplemented with fibrinogen variants. EXTEM (tissue factor as trigger) showed no clot 
formation in whole blood from the Fga-/- mice, When supplemented with WT, clot formation occurs 
and shows a similar profile to whole blood from a C57BL/6 mice (Figure 6—figure supplement 1). 
EXTEM showed extended clotting time for α390 (110.7 ± 18.5 s, p=0.7590) and more markedly α220 
(425.7 ± 111.4 s, p=0.0014) compared to WT (65.3 ± 16.8 s) (Figure 6A and B), consistent with the 
prolonged lag- phase observed in turbidity. Clot firmness was reduced for both truncations compared 
to WT (45.7 ± 6.3 mm), with α220 (7.0 ± 2.0 mm, p=0.0005) being the weakest and α390 displaying 
an intermediate phenotype (24 ± 8.5 mm, p=0.0099) (Figure 6C). The clot firmness trace for α220 
returned to baseline, with a similar but not complete decline for α390 (Figure 6A).
Figure 5. Whole blood clot contraction. Whole blood clots were prepared from whole blood from Fga-/- non- activated mice supplemented with either 
truncated fibrinogen or WT, no fibrinogen (controls). (A) Representative images of whole blood clot formation and contraction over time, showing 
the formation of a defined clot for WT and α390, but no visible clotting for α220 and controls. (B) Whole blood clot contraction kinetics was similar 
between α390 and WT, but not quantifiable for α220. (C) Final clot weight was not different between α390 and WT, but not quantifiable for α220. (D) 
The percentage of red blood cells incorporated in the contracted clot was similar between α390 and WT, whilst that of α220 was similar to the control 
containing tissue factor but no fibrinogen. Results shown as mean ± SD, n = 3, *p<0.05 by one- way ANOVA with Dunnett’s multiple comparison test 
relative to the tissue factor- activated control.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Retraction data (Figure 5B), weights (Figure 5C), and absorbances for red blood cell incorporation (Figure 5D).
Figure supplement 1. Clot incorporation of platelets.
Figure supplement 2. Recombinant fibrinogen is able to bind to platelets.
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ROTEM clots were then collected and prepared for SEM (Figure 6G). WT and α390 clots were 
composed of fibrin, platelets, and RBCs, while α220 clots showed limited fibrin and were mainly 
composed of RBCs and platelets. As limited fibrin was observed in α220 clots, the role of fibrino-
lysis in clot destabilisation was investigated using APTEM (includes aprotinin, an inhibitor of plasmin; 
Figure  6D). Similar to EXTEM, clotting time was extended (Figure  6E) for α390 (105.7 ± 15.0  s, 
p=0.3558) and α220 (335.0 ± 106.5 s, p=0.0141) compared to WT (63.7 ± 8.1 s). Clot firmness was 
higher in APTEM than in EXTEM for the truncations (α390, 31.3 ± 2.1 mm, p=0.0012; and α220, 15.7 
± 2.5 mm, p<0.0001), though still reduced compared to WT (45.3 ± 3.2 mm), and both were able to 
maintain clot firmness over the period of the experiment (Figure 6D and F). Fibrin was clearly present 
for α220 clots after APTEM, and numerous visible fibre ends were again visible (Figure 6G). These 
results indicate that fibrinolysis caused α220 clots to destabilise within 1 hr of clot formation in whole 
blood.
Figure 6. Fibrinolysis is the crucial factor for clot instability. Whole blood clots were prepared with whole blood from Fga-/- mice supplemented with 
either truncated or WT fibrinogens. (A) Whole blood clot formation curves from ROTEM, with clotting activated by tissue factor (EXTEM), showing clot 
firmness over time. (B) Clotting time was significantly increased for α220, but not α390, compared to WT. (C) Maximum clot firmness was significantly 
decreased for α390, and even further for α220, compared to WT. (D) Whole blood clot formation curves from ROTEM, with clotting activated by tissue 
factor and aprotinin to inhibit fibrinolysis (APTEM), showing clot firmness over time. (E) Clotting time was significantly increased for α220, but not α390, 
compared to WT. (F) Maximum clot firmness was significantly decreased for α390, and even further for α220, compared to WT. (G) Representative 
scanning electron microscopy images of clots collected and fixed after ROTEM analysis. Images taken on a SU8230 Ultra- High- Resolution Scanning 
Electron Microscope (Hitachi, Tokyo, Japan). Yellow arrow indicates fibrin, scale bar 5 µm. Results shown as mean ± SD, n = 3, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 by one- way ANOVA with Dunnett’s multiple comparison test (B, C, F) and Kruskal–Wallis test with Dunn’s multiple comparison 
test (E) relative to the WT.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. ROTEM firmness values (Figure 6A and D) and values generated by ROTEM for Figure 6B, C, E, and F.
Figure supplement 1. Comparison of ROTEM (EXTEM) profiles of C57BL/6 (Fga+/+), Fga-/-, and Fga-/- supplemented with 0.5 mg/mL recombinant WT 
(rWT).
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Discussion
Our main findings are that without the C- terminal domain (α390), fibrin produces a clot consisting 
of thinner fibres and composed of a denser structural network with reduced mechanical stability. 
However, and strikingly, without the whole of the αC- region and deletion of both the C- terminal 
domain and connector (α220), fibrin longitudinal growth is impaired significantly. Clots produced from 
α220 fibrinogen have stunted fibres and abnormal network structures that show drastically reduced 
mechanical and fibrinolytic resistance. These findings demonstrate a far greater role for the fibrinogen 
αC- region than hitherto thought, with it being critically important for normal fibrin fibre formation, 
growth, and clot stability.
The loss of the αC- domain in α390 produced a denser clot with thinner fibres compared to WT, 
as observed by both SEM and LSCM. These findings are reminiscent of a shorter fibrinogen variant 
α251 (Collet et al., 2005). Interestingly, the additional 139 AA residues in α390 did not seem to have 
affected final clot structure, which was largely similar to fibrin networks made from α251 fibrinogen 
(Gorkun et al., 1998; Collet et al., 2005). In contrast, the lack of 31 AA residues in α220, compared 
with α251, seems to significantly affect fibre growth and clot stability. It thus appears that the αC- con-
nector region, even if only partially present, rescues some of the fibre growth capabilities and the 
stability of α251 clots, which is greatly impaired when the full connector region is lost in α220.
The transition from longitudinal to lateral growth of protofibrils has been reported to occur at 
oligomer lengths of 0.6–0.8 µm (Hantgan et al., 2018; Chernysh et al., 2011). The AFM experi-
ments cannot extend to time points beyond protofibrils growth to 0.6 µm since this also coincides 
with network gelation. This notwithstanding, at earlier time points, there was comparable growth in 
protofibril length for WT and α390 fibrin, while α220 had significantly shorter oligomers at every time 
point. Moreover, LSCM and SEM data showed that the loss of the αC- connector results in short and 
stunted fibres. Taken together, these results indicate that α220 fibres are unable to support normal 
longitudinal fibre growth, which would normally lead to a continuous network of fibres without visible 
fibre ends. Previous data support our conclusions as clots made from fragment X2, where the C- termini 
of both α-chain end at residue 219, show visible fibre ends (Gorkun et al., 2002). Moreover, clots from 
fragment X2 demonstrated large pores, consistent with our finding with α220 variant, although fibre 
thickness was different, which may be due to the use of purified bovine fibrinogen or the partial loss 
of the β-chain during fragment X2 generation (Gorkun et al., 2002).
Previously our investigations with a recombinant fibrinogen Double- Detroit with mutations in both 
‘A’ and ‘B’ knobs resulted in defective knob- hole interactions, therefore preventing protofibril forma-
tion, lateral aggregation, and polymerisation (Duval et al., 2020). As there was no protofibril initiation 
and formation, the role of the αC- region in protofibril growth could not be detected. In our current 
αC- truncations, knob- hole interactions are unchanged, thus allowing protofibril initiation, but longitu-
dinal growth is impaired, altogether indicating a key role for the αC- subregions in protofibril growth, 
but not initiation.
The change in clot structure and altered cross- linking of fibrin fibres with the α220 variant is likely to 
contribute to the marked reduction in fibrin network stiffness compared with WT, and the instability of 
the clots even in the absence of FXIII. In agreement with this, Collet et al. were unable to study perme-
ation for α251 in the absence of FXIII due to clot weakness (Collet et al., 2005). Fibrinogen α251 is 
likely to be mechanically stronger than α220 as there are still at least two glutamine (Q221 [and/or 
223] and Q237) and lysine (K208 and K219) residues present that can be cross- linked by FXIII (Cilia 
La Corte et al., 2011). Moreover, our clot contraction data showed a reduction in RBC and platelet 
retention with α220 clots, while α390 and WT were largely similar. This is consistent with previous data 
using α251, which demonstrated that α-α cross- linking is essential for the retention of RBC within the 
clot (Byrnes et al., 2015).
The connector region also demonstrated a significant effect on susceptibility of the clot to lysis, 
which may have been due, at least in part, to altered clot structure, but there are other potential 
mechanisms. The α-chain has several lysine cleavage sites involved in fibrinolysis, AαK583, AαK230, 
and AαK206, before lysines in the coiled- coil of all three chains are targeted (Hudson, 2017). AαK583 
is the most vulnerable and leads to partially degraded fibrinogen within circulation (Hudson, 2017). 
As observed in both turbidimetric and ROTEM experiments for α220, there was a delay in the initial 
stages of clotting, providing opportunity for fibrinolysis to occur simultaneously with polymerisa-
tion. In addition, the conversion of fibrinogen to fibrin exposes t- PA and plasminogen binding sites, 
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namely, γ312–324 in the γ-nodule and Aα148–160 within the coiled- coil region (Yakovlev et al., 2000; 
Medved and Nieuwenhuizen, 2017). These sites are likely already exposed in α220 fibrinogen prior 
to their conversion to fibrin due to the lack of tethering of the αC- region to the coiled- coil and the 
E- region, in turn leading to early plasmin generation by t- PA (Veklich et al., 1993; Litvinov et al., 
2007). In support of this notion, α220 clots displayed rapid intrinsic lysis in whole blood when fibrino-
lysis was not inhibited (EXTEM) and in purified protein data, but not when lysis was inhibited in whole 
blood (APTEM). This observation was further confirmed by SEM of α220 clots after EXTEM experi-
ments, showing the presence of only minimal amounts of fibrin, whereas fibrin was clearly present 
throughout the clots after APTEM.
Intrinsic fibrinolysis was also enhanced in clots made from α390, as shown in EXTEM experiments, 
but to a lesser extent compared with α220. Similarly to α220, however, the effect on fibrinolysis was 
inhibited in APTEM experiments for α390. To complicate matters, turbidimetric analysis of external 
fibrinolysis showed no overall difference in lysis of α390 clots compared with WT. This is likely due to 
the denser clot structure in α390 that prevents movement of plasmin through the clot, thus counterbal-
ancing increased fibrinolysis initiation due to lack of the αC- domain (Collet et al., 2000). The denser 
clot structure observed in the purified system for α390 was less apparent in whole blood, indicating 
that blood cells prevent the formation of a denser clot. As for the difference in clot lysis comparing 
α390, α251 and α220, one mechanism may be related to the absence of the α2- antiplasmin cross- 
linking site Lys303 in both α251 and α220, resulting in reduced incorporation of this antifibrinolytic 
protein. Non- covalent interactions of α2- antiplasmin have also been reported for the D- region and the 
C- terminal subdomain of the αC- region, which could further play a role in different lysis patterns of 
clots made from these two variants (Tsurupa et al., 2010). Of note, our data also show an important 
mechanism for the interplay between clot mechanics and fibrinolysis, with both truncations failing to 
maintain clot firmness during ROTEM analysis, unlike WT. However, inhibition of fibrinolysis restored 
maintenance of clot firmness for both truncations, showing that in the absence of the αC- domain and/
or αC- connector, fibrinolysis is an important regulator of clot mechanical stability.
Our study had a number of limitations. Due to the low expression levels of the αC- truncation vari-
ants, any methodologies that required large amounts of protein, including, for example, in vivo throm-
bosis studies based on injection of the recombinant variants in Fga-/- mice, could not be performed. 
Limitations were also posed by the extreme weakness of the α220 variant, which could not be anal-
ysed in some of our experiments without cross- linking by FXIII. Future in vivo studies using mouse 
models with similar truncations may provide additional information on the role of the αC- region in 
physiological haemostasis and pathological thrombosis. However, as mentioned above, such models 
will likely be confounded by the effects of αC- truncations on both protein function and expression 
level.
In conclusion, our data show that the αC- domain and αC- connector play crucial and distinct roles 
in fibrin formation, fibre growth, clot structure, and clot stability. While the αC- domain is central to 
lateral aggregation, fibre thickness, and clot network density, the αC- connector, together with the 
αC- domain, is key for longitudinal fibre growth, continuity of fibrin fibres, and both mechanical and 
fibrinolytic clot stability. These novel functions of the αC- connector region enhance our understanding 
of the role of this fibrinogen region in clot formation, structure, and resistance to lysis. Moreover, our 
data have important ramifications for potential future therapies, targeting the αC- region of fibrinogen 
for the reduction of thrombosis risk.
Materials and methods
 Continued on next page
Key resources table 
Reagent type 
(species) or 
resource Designation Source or reference Identifiers Additional information
Genetic reagent 
(Mus musculus) Fga-/-
Kind gift from Dr Jay Degen, 
Cincinnati Children’s Hospital 
Medical Centre PMID:7649481
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Reagent type 
(species) or 
resource Designation Source or reference Identifiers Additional information
Genetic reagent 
(M. musculus) Fga+/-
Kind gift from Dr Jay Degen, 
Cincinnati Children’s Hospital 
Medical Centre PMID:7649481
Cell line (Cricetulus 
griseus) CHO-αβγ
Kind gift from Dr Susan Lord, 
University of North Carolina
Expressing WT human 
fibrinogen PMID:8418831
cell line (C. griseus) CHO-βγ
Kind gift from Dr Susan Lord, 
University of North Carolina
Expressing β- and 
γ-chain of human 
fibrinogen PMID:8418831
Cell line (C. 
griseus) CHO-αβ
Kind gift from Dr Susan Lord, 
University of North Carolina
Expressing α- and 





Kind gift from Dr Susan Lord, 
University of North Carolina PMID:8418831
Transfected 
construct
(human) pMLPAα390 This paper Ariëns Lab
Transfected 
construct




depleted plasma- purified 
fibrinogen Merck 341578
Biological sample 
(human) Glu- plasminogen Enzyme Research Laboratories HPG 2001
Biological sample 




(PPP reagent) Stago 86193
Biological sample 
(human) Thrombin Merck 605190
Antibody
CD41 Alexa Fluor 700 
(anti- mouse monoclonal) 
(MWReg30) BioLegend 133925 (5 µg/mL)
Antibody
CD62P PE (anti- mouse 
monoclonal) (RMO- 1) BioLegend 148305 (10 µg/mL)
Antibody
CD63 APC (anti- mouse 
monoclonal) (NVG- 2) BioLegend 143905 (5 µg/mL)
Antibody
IgG2a PE (monoclonal 
Mouse)
(MOPC- 173) BioLegend 400211 (10 µg/mL)
Antibody
IgG2a APC (monoclonal Rat) 
(RTK 2758) BioLegend 400511 (5 µg/mL)
Antibody
FITC fibrinogen (anti- human 
polyclonal) Agilent Technologies F0111 (60 µg/mL)
Peptide, 
recombinant 
protein (human) WT This paper




protein (human) α390 This paper
Purified from CHO cells, fibrinogen 
with α-chain truncated at α390, 
Ariëns Lab
 Continued
 Continued on next page
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Reagent type 
(species) or 
resource Designation Source or reference Identifiers Additional information
Peptide, 
recombinant 
protein (human) α220 This paper
Purified from CHO cells, fibrinogen 




protein (human) γ′/γ′ This paper
Purified from CHO cells, fibrinogen 
homozygous in γ′- chain, Ariëns Lab
Peptide, 
recombinant 
protein (human) t- PA Pathway Diagnostics TC41072
Chemical 
compound, drug PAR4 Cambridge BioScience ANA60218- 5
Commercial assay 
or kit
Alexa Fluor 488 using a 
protein labelling kit Thermo Fisher Scientific A10235
Commercial assay 
or kit
QuikChange II Site- Directed 
Mutagenesis Kit Agilent Technologies 200524
Software, algorithm ImageJ software ImageJ (http:// imagej. nih. gov/ ij/) RRID:SCR_003070
Software, algorithm GraphPad Prism
GraphPad Prism (https:// graphpad. 
com) RRID:SCR_015807 Version 8
Software, algorithm MATLAB MathWorks (http:// mathorks. com) RRID:SCR_001622
Software, algorithm OriginLab OriginLab (http:// originlab. com) RRID:SCR_014212
Other Dynabeads M- 450 Epoxy Invitrogen 14011
 Continued
Materials
Human thrombin and human plasminogen- depleted plasma- purified fibrinogen were purchased 
from Merck (Cramlington, UK) and reconstituted in double- distilled water (ddH2O). Tissue plasmin-
ogen activator (t- PA) was from Pathway Diagnostics (Dorking, UK) and human Glu- plasminogen from 
Enzyme Research Laboratories (Swansea, UK) and were prepared in ddH2O. Human FXIII from Zedira 
(Darmstadt, Germany) was further purified from contaminating albumin and glucose by Hiload 16/60 
superdex 200 (GE Healthcare, Little Chalfont, UK) gel filtration as previously described (Hethershaw 
et al., 2014). All purified proteins were stored at –80°C  prior to use. All other chemicals used were 
obtained from Sigma- Aldrich (Gillingham, UK) unless stated otherwise.
Experimental animals
All animals were maintained in individually ventilated cages, at 21°C  with 50–70% humidity, light/dark 
cycle 12/12 hr, and on standard diet ad libitum. Fibrinogen knockout (Fga)-/- mice (Suh et al., 1995), on 
C57BL/6 background, were generated by crossing male Fga-/- with female Fga+/- mice, and genotypes 
were determined using real- time PCR (Transnetyx, Cordova, USA). Mice were bled for whole blood 
contraction and rotational thromboelastometry experiments. Procedures were performed according 
to accepted standards of humane animal care, approved by the ethical review committee at the 
University of Leeds, and conducted under licence from the United Kingdom Home Office.
Cloning and recombinant fibrinogen expression
Two truncated recombinant fibrinogen α-chain variants (α220 and α390) were produced using Quik-
Change II Site- Directed Mutagenesis Kits from Agilent Technologies (Stockport, UK) on the human 
full- length fibrinogen α610 cDNA and expressed in Chinese hamster ovary (CHO) cells as previously 
described (Lord and Binnie, 1993; Macrae et al., 2018). In brief, primers were designed to create 
stop codons in the cDNA sequence in the expression vector pMLP. Fibrinogen α390 was truncated 
after aspartate 390, and α220 terminated after serine 220. Truncations were confirmed by sequencing 
using MRC PPU DNA Sequencing and Services (University of Dundee, UK). The truncated plasmids 
were co- transfected into CHO cells already expressing the human fibrinogen β- and γ-chains, with a 
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second plasmid used for selection (pMSV- his). Expression and purification of recombinant fibrinogen 
was performed as previously described (Takebe et al., 1995; Macrae et al., 2018). Recombinant 
homodimer fibrinogen γ′ was produced in CHO-αβ cells transfected with pMLP vector containing 
mRNA of fibrinogen γ′, expressed and purified as described above. For α390 and α220 fibrinogens, 
the α-chain size was reduced from 66 kDa to 42 kDa and 25 kDa, respectively. No changes were made 
to the β- and γ-chains in these variants. The assembled fibrinogen was reduced to 290 kDa for α390 
and 256 kDa for α220, from 340 kDa for wild- type (WT). CHO expressing WT fibrinogen, expressing 
α- and β-chain (CHO-αβ) and β- and γ-chain (CHO-βγ) were kindly provided by Dr Susan Lord. Several 
recombinant batches of both the truncations and WT were used for experiments. Cells were negative 
for mycoplasma.
NativePAGE
Using the NativePAGE system from Thermo Fisher Scientific 1  μg of recombinant fibrinogen was 
added to 1× sample buffer and loaded onto a NativePAGE Novex 3–12% Bis- Tris protein gel. The 
gel was run at 150 V for 60 min and then 250 V for a further 60 min. The gel was fixed in a solution of 
40%  methanol and 10%  acetic acid and then heated for 45 s, incubated on a shaker for 30 min, then 
stained with 0.02% R- 250 in 30%  methanol and 10%  acetic acid, heated for 45 s, and incubated for 
30 min. It was destained with 8%  acetic acid, heated again for 45 s, and left to destain for 2 hr and 
imaged using a G:Box (Syngene, Cambridge, UK).
SDS-PAGE
Integrity of the recombinant fibrinogen chains was assessed by sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS- PAGE) using the NuPAGE system (Thermo Fisher Scientific). Recom-
binant fibrinogen (2.5 µg) was added to 1×  reducing sample buffer and 1×  LDS sample buffer and 
denatured at 95°C   for 10 min, then loaded onto 4–12% NuPAGE Bis- Tris gel. The gel was run at 
160  V until adequate separation of the three fibrinogen chains, stained with InstantBlue (Abcam, 
Cambridge, UK), and imaged on a G:Box.
Fibrin clot formation and external fibrinolysis
Recombinant fibrinogens were diluted in Tris buffered saline (TBS; 50 mM Tris and 100 mM NaCl at pH 
7.5) to a final concentration of 0.5 mg/mL (1.47 μM) in triplicate on a 384- well microtitre plate (Greiner 
Bio- One, Stroud, UK). Clotting was initiated by the addition of 0.1 U/mL thrombin and 5 mM CaCl2 to 
each well. Clot progression was monitored on a PowerWave microplate spectrophotometer (Bio- Tek, 
Swindon, UK) every 12 s at wavelength of 340 nm, for 2 hr at 37°C.  After 2 hr, a lysis mix composed of 
Glu- plasminogen and t- PA in TBS (final concentrations of 0.24 μM and 1 nM, respectively) was added 
to each well and the plate was read as described above for a further 4 hr. The assay was repeated four 
times and samples were prepared in triplicate.
Fibrin fibre arrangement and lysis by scanning confocal microscopy
Each recombinant fibrinogen (truncated variants and WT) was labelled with Alexa Fluor 488 using a 
protein labelling kit (Thermo Fisher Scientific). Recombinant fibrinogens with a final concentration 
of 0.475 mg/mL (1.4 μM) were prepared in TBS, and 25 μg/mL of the corresponding Alex Fluor 488 
labelled fibrinogen was added. An activation mixture of CaCl2 and thrombin at a final concentration of 
5 mM and 0.1 U/mL, respectively, was used to initiate clotting. The sample was added to a µ-slide VI 
(Thistle Scientific, Glasgow, UK) and allowed to form in a humidity chamber for 1 hr before imaging. 
Clots were imaged on a LSM880 inverted laser scanning confocal microscope (Zeiss, Cambridge, UK) 
using a ×40 magnification oil objective, and z- stacks were taken of the middle of the clot (29 slices 
every 0.7 µm over 20.3 µm) in random areas of the slide. Images were analysed in ImageJ (National 
Institutes of Health, Bethesda, MD) using an in- house macro to determine fibre count. Clots were 
prepared on three separate occasions. Fibrinolysis was performed on a clot formed as described 
above in the µ-slide VI where a lysis mix (plasminogen 0.4 μM and t- PA 6 nM) was added to one side 
of the slide. Clots were incubated for 15 min to allow perfusion of the lysis mix into the fibrin network. 
The lysis front was found, and its movement was viewed using the same objective and similar z- stack 
settings as above (×40 magnification oil objective, z- stacks every 0.6 µm over 20.3 µm).
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Clot structure by scanning electron microscopy
Recombinant fibrinogen with a final concentration of 1 mg/mL (2.94 μM) was clotted in a pierced 
Eppendorf lid with the addition of 1 U/mL thrombin and 5 mM CaCl2 and incubated in a humidity 
chamber for 2 hr. After incubation, the clots were washed three times with 0.05 M sodium cacodylate 
buffer (pH 7.4), fixed overnight in 2%  glutaraldehyde prepared in 0.05 M sodium cacodylate. Then the 
next day, clots were washed a further three times with sodium cacodylate. Clots were dehydrated with 
increasing percentage of acetone (30, 50, 70, 80, 80, 95, and 100%). The clots were finally subjected 
to critical- point drying and sputter- coating with 5 nm iridium, before imaging on a SU8230 Ultra- High- 
Resolution Scanning Electron Microscope (Hitachi, Tokyo, Japan) diameter was measured in ImageJ.
Protofibril analysis by atomic force microscopy
Fibrin protofibrils and oligomers were analysed using AFM. AFM experiments were performed on the 
surface of freshly cleaved mica treated with 50 µL of 2 mM NiCl2 for 5 min. After 5 min, the surface was 
rinsed with ddH2O and dried with nitrogen gas. For initiation of fibrin polymerisation, a final concen-
tration of 0.02 mg/mL (59 nM) fibrinogen was added to a final concentration of 0.05 U/mL thrombin 
and 2 mM CaCl2. Due to the swiftness of fibrin polymerisation, the samples were diluted so that the 
polymer formation could be monitored at 10, 20, and 30 min. After the desired time, polymerisa-
tion was interrupted by diluting the polymerising solution a further three times with TBS, followed 
immediately by the addition of 3 µL of the diluted solution to the surface of pre- treated mica for 10 s. 
150 µL of deionised water was then placed onto the substrate for 10 s and removed with nitrogen gas. 
Imaging of polymers was done using a Nanoscope IV Dimension 3100 AFM (Bruker, Santa Barbara, 
CA) in tapping mode with a scan rate of 0.8 Hz. Measurements were performed in air using silicon 
cantilevers (TESPA- V2, Bruker) with a typical radius of 7 nm. Five images were taken from each sample, 
and 3–4  samples were used for each time point. Images were processed using NanoScope Anal-
ysis software. Standard flattening of images was performed, and no resolution enhancement was 
used. Polymer lengths were measured using ImageJ software. Statistical analysis was performed using 
OriginLab software (OriginLab Corporation, Northampton, MA).
Cross-linking experiments
Reaction mixtures composed of 5 µg recombinant fibrinogen variants and 5 mM CaCl2 were mixed 
with 15 µg/mL FXIII in TBS and followed immediately with the addition of 0.1 U/mL thrombin to acti-
vate clotting. The reaction was stopped at 0, 2, 15, 30, 60, and 120 min with a stop solution containing 
1×  NuPAGE reducing sample buffer and 1×  NuPAGE LDS sample buffer in TBS and immediately 
denatured at 95°C  for 10 min and incubated on ice until all time points were completed. The samples 
were run on a 4–12% NuPAGE Bis- Tris gel at 160 V until adequate separation of the bands. Gels 
were stained with InstantBlue and imaged on a G:Box. The band densitometry was calculated using 
ImageJ, the α-chains were normalised to the β-chains, and the percentage remaining was calculated 
for each time point.
Fibrin microrheology
Fibrin clot viscoelastic properties were assessed by microrheology using magnetic tweezers as previ-
ously described (Allan et al., 2012; Baker et al., 2019). In brief, recombinant fibrin clots were made 
with 0.5 mg/mL (1.47 µM) fibrinogen, 5 mM CaCl2 either in the presence or absence of 3.6 µg/mL of 
FXIII. Superparamagnetic beads, 4.5 µm in diameter, were diluted at 1:250 (v:v) (Dynabeads M- 450 
Epoxy, Invitrogen, Paisley, UK) were added to the mixture before clotting was initiated with 0.1 U/mL 
thrombin and then quickly transferred to 0.5 mm diameter capillary tubes (CM Scientific, Keighley, 
UK). Capillary tube ends were sealed with petroleum jelly to prevent dehydration, and clots could 
fully form overnight at room temperature. Measurements were collected by applying a force to the 
paramagnetic beads using four electromagnets to produce a magnetic field gradient. The electro-
magnets were placed around the sample platform of an Olympus IX71 inverted microscope, which 
was connected to a CCD camera. Capillary tubes were mounted above the ×40   objective of the 
microscope. Bead displacement was collected through Labview 7.1 software (National Instruments, 
Newbury, UK). The displacement of 10 random, individual beads throughout the clot was measured 
per sample, and this was repeated at least three times.
 Research article Cell Biology | Structural Biology and Molecular Biophysics
McPherson et al. eLife 2021;10:e68761. DOI: https:// doi. org/ 10. 7554/ eLife. 68761  16 of 20
Clot contraction
Clot contraction was investigated using a method modified from Aleman et al., 2014. 1 mL micro 
test tubes (Alpha Laboratories, Eastleigh, UK) were coated with Sigmacote, washed with ddH2O, 
and left to dry overnight. The following morning, blood was collected from the inferior vena cava of 
Fga-/- mice into 10% v/v 109 mM trisodium citrate. Whole blood was diluted 1:3 in TBS and reconsti-
tuted with a final concentration of 0.5 mg/mL (1.47 µM) recombinant human fibrinogen. Clotting was 
initiated by adding an activation mix of 1 pM tissue factor (Stago, Reading, UK) and 10 mM CaCl2. 
Two tubes containing Fga-/- blood were used as controls, one of which had the activation mix added. 
Subsequently, images were taken every 30 min for 2 hr, before clots were removed from the tubes and 
weighed. The non- activated and activated samples were collected and used to quantify the RBC and 
platelet incorporation into the clot. A sample of non- activated reconstituted blood was taken before 
activation, and the activated sample was taken after 2 hr. Clot contraction was quantified between 
1 and 2 hr using ImageJ. Haemoglobin assay was used to assess RBC incorporation, non- activated 
and activated samples were diluted in ddH2O and incubated for 30 min to allow haemolysis, and 
absorbency was read at 415 nm. RBC incorporation in the clot (%) was calculated as follows: ((pre- 
OD415- post- OD415)/pre- OD415 × 100). To quantify the incorporation of platelets into the retracted clot, 
equal aliquots of non- activated and activated samples were diluted 1 in 10 in modified Tyrodes buffer 
(150 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM 
glucose, pH 7.4) and stained with 5 µg/mL anti- CD41- AF700 (BioLegend) for 15 min. This was further 
diluted (1:100 in PBS), and CD41- positive events were acquired for 2.5 min at a flow rate of 10 µL/
min on a CytoFLEX RUO flow cytometer (Beckman Coulter) and relative events/µL compared using 
CytExpert (2.1; Beckman Coulter). The assay was repeated three times.
Platelet-fibrinogen interaction
Flow cytometry was used to investigate platelet- fibrinogen interaction. An antibody staining cocktail 
of 60 µg/mL anti- fibrinogen FITC (Agilent Technologies, Cheadle, UK), 10 µg/mL CD62P- PE, 5 µg/
mL CD63- APC, 5 µg/mL CD41- AF700 (BioLegend, London, UK) was added to 15 µg fibrinogen (WT, 
α390, α220, and γ′/γ′) in modified Tyrodes buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 
7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM glucose, pH 7.4). Followed by agonists, PAR4 
(200 µM) or ADP (10 µM), or no agonist for basal activity. 5 µL of whole blood collected in 10% v/v 
109 mM trisodium citrate from Fga-/- mice was added and rapidly mixed. Tubes were incubated for 
20 min in the dark, then fixed with 1%  paraformaldehyde in phosphate buffered saline. Control tubes 
were set up with fibrinogen, CD41- AF700, IgG- PE, IgG- APC, PAR4 (200 µM), and EDTA (10 mM). 
Samples were acquired on a two- laser four- detector CytoFLEX RUO flow cytometer (Beckman, High 
Wycombe, UK) and platelets were gated based on their characteristic SSC/FFC profile in combination 
with a CD41- positive gate, and 10,000 positive events were recorded. Analysis was performed using 
CytExpert (2.1) to extract MFI values and calculate percentage positive cells based on 2%  gates on 
the background fluorescence of isotype or internal controls, and the assay was repeated three times. 
Fibrinogen γ′/γ′ was used as a control as it lacks the C- terminal AGDV residues, known to bind to the 
platelet integrin αIIbβ3 (Farrell et al., 1992).
Rotational thromboelastometry
Whole blood clot formation and firmness were analysed using a ROTEM Delta (Werfen Limited, 
Warrington, UK). All investigations were performed through activation of the extrinsic pathway using 
the EXTEM and APTEM tests. Both tests use tissue factor as an agonist with the EXTEM test influ-
enced by extrinsic coagulation factors, platelets, and fibrinogen. In contrast, the APTEM test allows 
for the investigation of fibrinolysis, which is based on the EXTEM test but with the addition of apro-
tinin to inhibit fibrinolytic proteins. Fga-/- mice were bled as described for clot contraction, and the 
collected blood was reconstituted with recombinant fibrinogen at a final concentration of 0.5 mg/mL 
(1.47 µM). The assays were repeated three times each. The clot contents of the cups were collected 
afterwards and fixed overnight in 2.5%  glutaraldehyde prepared in 0.9%  NaCl (VWR International, 
Lutterworth, UK). The following morning, clots were washed three times with 0.05 M sodium caco-
dylate (pH 7.4), dehydrated, critical- point dried, and sputter- coated as described in the clot structure 
by scanning electron microscopy.
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Statistical analysis
Statistical analysis of experimental data was performed with GraphPad Prism v7 (La Jolla, CA, USA) or 
OriginLab software (OriginLab Corporation, Northampton, MA), with p<0.05 considered as statisti-
cally significant. In all data sets, the results were compared to the control, WT, or pre- treated sample. 
Data was tested for normality before statistical analysis by ANOVA or Kruskal–Wallis test, followed by 
post- hoc test of Dunnett, Dunn, or Sidak multiple comparison test. The number of experiments and 
the statistical tests used for each experiment are detailed in the respective figure legends. Error bars 
shown as ± standard deviation in all experiments except for early fibrin polymers length which are 
±interquartile range.
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